Publicaciones en colaboración con investigadores/as de Fundación Jiménez Díaz (12)

2021

  1. A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer

    Genome Medicine, Vol. 13, Núm. 1

  2. Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses

    Gut, Vol. 70, Núm. 2, pp. 319-329

  3. Gallbladder disease and pancreatic cancer risk: a multicentric case-control European study

    European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), Vol. 30, Núm. 6, pp. 423-430

2020

  1. Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Vol. 29, Núm. 5, pp. 1009-1018

  2. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 21, Núm. 3, pp. 387-397

  3. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 14, pp. 1505-1517

2019

  1. Observational Prospective Study to Determine the Evolution of the Symptomatic Profile of Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients and Its Relation to the Control of the Disease

    Advances in Therapy, Vol. 36, Núm. 6, pp. 1497-1508

2018

  1. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer

    New England Journal of Medicine, Vol. 378, Núm. 22, pp. 2078-2092

  2. Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor–Targeted Agents

    Clinical Genitourinary Cancer, Vol. 16, Núm. 4, pp. e777-e784

2017

  1. Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib

    Scientific Reports, Vol. 7

2013

  1. Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study

    British Journal of Cancer, Vol. 109, Núm. 1, pp. 121-130

  2. Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study

    British Journal of Cancer, Vol. 108, Núm. 12, pp. 2565-2572